Novel rate-area-shape modeling approach to quantify bacterial killing and regrowth for in vitro static time-kill studies

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 381-388

  Cheah, Soon Ee ^a   Li, Jian ^a   Nation, Roger L ^a   Bulitta, Jürgen B ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; DORIPENEM; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ACINETOBACTER BAUMANNII; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; CHEMICAL MODEL; COLONY FORMING UNIT; CONTROLLED STUDY; IN VITRO STUDY; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; BACTERIAL COUNT; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; STATISTICAL MODEL;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; CARBAPENEMS; COLISTIN; COLONY COUNT, MICROBIAL; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL;

EID: 84920175487     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04182-14     Document Type: Article

References (32)

1. Walker B, Barrett S, Polasky S, Galaz V, Folke C, Engstrom G, Ackerman F, Arrow K, Carpenter S, Chopra K, Daily G, Ehrlich P, Hughes T, Kautsky N, Levin S, Maler KG, Shogren J, Vincent J, Xepapadeas T, de Zeeuw A.2009. Environment. Looming global-scale failures and missing institutions. Science 325:1345-1346. http://dx.doi.org/10.1126/science.1175325.
2. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12. http://dx.doi.org/10.1086/595011.
3. Spellberg B, Bartlett JG, Gilbert DN. 2013. The future of antibiotics and resistance. N Engl J Med 368:299-302. http://dx.doi.org/10.1056 /NEJMp1215093.
4. Mouton JW, Ambrose PG, Canton R, Drusano GL, Harbarth S, MacGowan A, Theuretzbacher U, Turnidge J. 2011. Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Updat 14:107-117. http://dx.doi.org/10.1016/j.drup.2011.02.005.
5. Singh R, Tam VH. 2011. Optimizing dosage to prevent emergence of resistance-lessons from in vitro models. Curr Opin Pharmacol 11:453-456. http://dx.doi.org/10.1016/j.coph.2011.07.009.
6. Bergen PJ, Li J, Nation RL. 2011. Dosing of colistin-back to basic PK/PD. Curr Opin Pharmacol 11:464-469. http://dx.doi.org/10.1016/j.coph .2011.07.004.
7. Lim TP, Lee W, Tan TY, Sasikala S, Teo J, Hsu LY, Tan TT, Syahidah N, Kwa AL. 2011. Effective antibiotics in combination against extreme drug-resistant Pseudomonas aeruginosa with decreased susceptibility to polymyxin B. PLoS One 6:e28177. http://dx.doi.org/10.1371/journal .pone.0028177.
8. Lim TP, Tan TY, Lee W, Sasikala S, Tan TT, Hsu LY, Kwa AL. 2011. In-vitro activity of polymyxin B, rifampicin, tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii in Singapore. PLoS One 6:e18485. http://dx.doi.org/10.1371/journal.pone.0018485.
9. Tam VH, Schilling AN, Vo G, Kabbara S, Kwa AL, Wiederhold NP, Lewis RE. 2005. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 49:3624-3630. http://dx.doi. org/10.1128/AAC.49.9.3624-3630.2005.
10. Poudyal A, Howden BP, Bell JM, Gao W, Owen RJ, Turnidge JD, Nation RL, Li J. 2008. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother 62: 1311-1318. http://dx.doi.org/10.1093/jac/dkn425.
11. Owen RJ, Li J, Nation RL, Spelman D. 2007. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 59:473-477. http://dx.doi.org/10.1093/jac/dkl512.
12. Lin G, Pankuch GA, Appelbaum PC, Kosowska-Shick K. 2012. Activity of telavancin compared to other agents against coagulase-negative staphylococci with different resistotypes by time kill. Diagn Microbiol Infect Dis 73:287-289. http://dx.doi.org/10.1016/j.diagmicrobio.2012.04.003.
13. Vidaillac C, Parra-Ruiz J, Rybak MJ. 2011. In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin. Diagn Microbiol Infect Dis 71:470-473. http://dx.doi.org/10.1016/j.diagmicrobio.2011.09.002.
14. Albur M, Noel A, Bowker K, MacGowan A. 2012. Bactericidal activity of multiple combinations of tigecycline and colistin against NDM-1-producing Enterobacteriaceae. Antimicrob Agents Chemother 56:3441-3443. http://dx.doi.org/10.1128/AAC.05682-11.
15. Mattie H, Sekh BA, van Ogtrop ML, van Strijen E. 1992. Comparison of the antibacterial effects of cefepime and ceftazidime against Escherichia coli in vitro and in vivo. Antimicrob Agents Chemother 36:2439-2443. http://dx.doi.org/10.1128/AAC.36.11.2439.
16. van Ogtrop ML, Mattie H, Guiot HF, van Strijen E, Hazekamp-van Dokkum AM, van Furth R. 1990. Comparative study of the effects of four cephalosporins against Escherichia coli in vitro and in vivo. Antimicrob Agents Chemother 34:1932-1937. http://dx.doi.org/10.1128/AAC.34.10 .1932.
17. Tsuji BT, Yang JC, Forrest A, Kelchlin PA, Smith PF. 2008. In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus. J Antimicrob Chemother 62:156-160. http://dx.doi.org/10.1093 /jac/dkn133.
18. Czock D, Keller F. 2007. Mechanism-based pharmacokineticpharmacodynamic modeling of antimicrobial drug effects. J Pharmacokinet Pharmacodyn 34:727-751. http://dx.doi.org/10.1007/s10928-007-9069-x.
19. Tsuji BT, Okusanya OO, Bulitta JB, Forrest A, Bhavnani SM, Fernandez PB, Ambrose PG. 2011. Application of pharmacokineticpharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead. Clin Infect Dis 52(Suppl 7):S513-S519. http://dx.doi.org/10.1093/cid/cir166.
20. Harigaya Y, Bulitta JB, Forrest A, Sakoulas G, Lesse AJ, Mylotte JM, Tsuji BT. 2009. Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia. Antimicrob Agents Chemother 53:3894-3901. http://dx.doi.org/10.1128/AAC.01585-08.
21. Nielsen EI, Friberg LE. 2013. Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacol Rev 65:1053-1090. http://dx.doi. org/10.1124/pr.111.005769.
22. Brown AM. 2001. A step-by-step guide to non-linear regression analysis of experimental data using a Microsoft Excel spreadsheet. Comput Methods Programs Biomed 65:191-200. http://dx.doi.org/10.1016/S0169 -2607(00)00124-3.
23. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, Liolios L. 2006. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 50:2946-2950. http://dx.doi. org/10.1128/AAC.00103-06.
24. Mouton JW, Vinks AA. 2005. Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clin Pharmacokinet 44:201-210. http://dx.doi.org/10.2165 /00003088-200544020-00005.
25. Staneva M, Markova B, Atanasova I, Terziivanov D. 1994. Pharmacokinetic and pharmacodynamic approach for comparing two therapeutic regimens using amikacin. Antimicrob Agents Chemother 38:981-985. http://dx.doi.org/10.1128/AAC.38.5.981.
26. Regoes RR, Wiuff C, Zappala RM, Garner KN, Baquero F, Levin BR. 2004. Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob Agents Chemother 48: 3670-3676. http://dx.doi.org/10.1128/AAC.48.10.3670-3676.2004.
27. Bouvier d'Yvoire MJY, Maire PH. 1996. Dosage regimens of antibacterials. Clin Drug Investig 11:229-239. http://dx.doi.org/10.2165/00044011 -199611040-00006.
28. MacGowan AP, Bowker KE, Noel AR. 2008. Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection. Antimicrob Agents Chemother 52:1401-1406. http: //dx.doi.org/10.1128/AAC.01153-07.
29. Okusanya OO, Tsuji BT, Bulitta JB, Forrest A, Bulik CC, Bhavnani SM, Fernandes P, Ambrose PG. 2011. Evaluation of the pharmacokineticspharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection. Diagn Microbiol Infect Dis 70:101-111. http://dx.doi.org /10.1016/j.diagmicrobio.2011.03.001.
30. Firsov AA, Lubenko IY, Portnoy YA, Zinner SH, Vostrov SN. 2001. Relationships of the area under the curve/MIC ratio to different integral endpoints of the antimicrobial effect: gemifloxacin pharmacodynamics in an in vitro dynamic model. Antimicrob Agents Chemother 45:927-931. http://dx.doi.org/10.1128/AAC.45.3.927-931.2001.
31. Begic D, von Eiff C, Tsuji BT. 2009. Daptomycin pharmacodynamics against Staphylococcus aureus hemB mutants displaying the small colony variant phenotype. J Antimicrob Chemother 63:977-981. http://dx.doi. org/10.1093/jac/dkp069.
32. Tam VH, Chang KT, Yang Z, Newman J, Hu M. 2013. In vitro pharmacodynamics of AZD5206 against Staphylococcus aureus. Antimicrob Agents Chemother 57:1062-1064. http://dx.doi.org/10.1128/AAC.01208-12.